Replimune Group (NASDAQ:REPL) Rating Increased to Outperform at BMO Capital Markets

Replimune Group (NASDAQ:REPL) was upgraded by BMO Capital Markets from an “underperform” rating to an “outperform” rating in a report released on Tuesday, MarketBeat Ratings reports. The brokerage presently has a $16.00 target price on the stock. BMO Capital Markets’ price target suggests a potential upside of 42.86% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on REPL. Wedbush lifted their price objective on shares of Replimune Group from $6.00 to $9.00 and gave the company a “neutral” rating in a research report on Tuesday. Wall Street Zen upgraded shares of Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Jefferies Financial Group reiterated a “hold” rating and issued a $2.00 price target (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. HC Wainwright reissued a “sell” rating on shares of Replimune Group in a report on Monday, April 13th. Finally, Weiss Ratings upgraded Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 18th. Two research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $8.12.

Replimune Group Price Performance

Shares of Replimune Group stock opened at $11.20 on Tuesday. The stock’s 50-day simple moving average is $6.41 and its 200-day simple moving average is $7.29. Replimune Group has a 52 week low of $1.50 and a 52 week high of $13.24. The company has a market capitalization of $924.78 million, a price-to-earnings ratio of -3.26 and a beta of 0.88. The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). As a group, analysts expect that Replimune Group will post -3.39 earnings per share for the current fiscal year.

Insider Transactions at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the sale, the insider directly owned 180,962 shares in the company, valued at $1,672,088.88. This represents a 6.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by company insiders.

Institutional Trading of Replimune Group

Several hedge funds and other institutional investors have recently bought and sold shares of REPL. International Assets Investment Management LLC purchased a new position in Replimune Group during the fourth quarter worth $29,000. Russell Investments Group Ltd. raised its stake in shares of Replimune Group by 3,638.9% in the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after acquiring an additional 7,569 shares during the period. CWM LLC lifted its holdings in shares of Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after acquiring an additional 2,886 shares during the last quarter. Essential Partners LLC lifted its holdings in shares of Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after acquiring an additional 5,624 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in shares of Replimune Group by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after purchasing an additional 6,873 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.